1
|
Ghazanfari N, van Waarde A, Doorduin J, Sijbesma JWA, Kominia M, Koelewijn M, Attia K, Willemsen ATM, Visser TJ, Heeres A, Dierckx RAJO, de Vries EFJ, Elsinga PH. Pharmacokinetic Modeling of [ 11C]GSK-189254, PET Tracer Targeting H 3 Receptors, in Rat Brain. Mol Pharm 2022; 19:918-928. [PMID: 35170965 PMCID: PMC8905578 DOI: 10.1021/acs.molpharmaceut.1c00889] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
![]()
The histamine H3 receptor has been considered as a target
for the treatment of various central nervous system diseases. Positron
emission tomography (PET) studies with the radiolabeled potent and
selective histamine H3 receptor antagonist [11C]GSK-189254 in rodents could be used to examine the mechanisms of
action of novel therapeutic drugs or to assess changes of regional
H3 receptor density in animal models of neurodegenerative
disease. [11C]GSK-189254 was intravenously administered
to healthy Wistar rats (n = 10), and a 60 min dynamic
PET scan was carried out. Arterial blood samples were obtained during
the scan to generate a metabolite-corrected plasma input function.
PET data were analyzed using a one-tissue compartment model (1T2k),
irreversible (2T3k) or reversible two-tissue compartment models (2T4k),
graphical analysis (Logan and Patlak), reference tissue models (SRTM
and SRTM2), and standard uptake values (SUVs). The Akaike information
criterion and the standard error of the estimated parameters were
used to select the most optimal quantification method. This study
demonstrated that the 2T4k model with a fixed blood volume fraction
and Logan graphical analysis can best describe the kinetics of [11C]GSK-189254 in the rat brain. SUV40–60 and the reference tissue-based measurements DVR(2T4k), BPND(SRTM), and SUV ratio could also be used as a simplified method to
estimate H3 receptor availability in case blood sampling
is not feasible.
Collapse
Affiliation(s)
- Nafiseh Ghazanfari
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Aren van Waarde
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Janine Doorduin
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Jürgen W A Sijbesma
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Maria Kominia
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | | | - Khaled Attia
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Antoon T M Willemsen
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | | | | | - Rudi A J O Dierckx
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Erik F J de Vries
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| | - Philip H Elsinga
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen 9700 RB, The Netherlands
| |
Collapse
|
2
|
Takamura Y, Kakuta H. In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography. J Med Chem 2021; 64:5226-5251. [PMID: 33905258 DOI: 10.1021/acs.jmedchem.0c01714] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Positron emission tomography (PET) is useful for noninvasive in vivo visualization of disease-related receptors, for evaluation of receptor occupancy to determine an appropriate drug dosage, and for proof-of-concept of drug candidates in translational research. For these purposes, the specificity of the PET tracer for the target receptor is critical. Here, we review work in this area, focusing on the chemical structures of reported PET tracers, their Ki/Kd values, and the physical properties relevant to target receptor selectivity. Among these physical properties, such as cLogP, cLogD, molecular weight, topological polar surface area, number of hydrogen bond donors, and pKa, we focus especially on LogD and LogP as important physical properties that can be easily compared across a range of studies. We discuss the success of PET tracers in evaluating receptor occupancy and consider likely future developments in the field.
Collapse
Affiliation(s)
- Yuta Takamura
- Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 1-1-1, Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
| | - Hiroki Kakuta
- Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 1-1-1, Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
| |
Collapse
|
3
|
The chemistry of labeling heterocycles with carbon-11 or fluorine-18 for biomedical imaging. ADVANCES IN HETEROCYCLIC CHEMISTRY 2020. [DOI: 10.1016/bs.aihch.2019.11.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
4
|
Dahl K, Nakao R, Amini N, Moein MM, Finnema S, Malmquist J, Varnäs K, Schou M. Development of [ Carbonyl- 11C]AZ13198083, a Novel Histamine Type-3 Receptor Radioligand with Favorable Kinetics. ACS Chem Neurosci 2018; 9:906-911. [PMID: 29359917 DOI: 10.1021/acschemneuro.7b00493] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The histamine subtype-3 receptor (H3R) is implicated in a range of central nervous system disorders, and several radioligands have been developed for H3R positron emission tomography imaging. However, a limitation of currently used PET radioligands for H3R is the slow binding kinetics in high density brain regions. To address this, we herein report the development of three novel candidate H3R radioligands, namely, [ carbonyl-11C]AZ13153556 ([ carbonyl-11C]4), [ carbonyl-11C]AZD5213([ carbonyl-11C]5), and [ carbonyl-11C]AZ13198083 ([ carbonyl-11C]6), and their subsequent preclinical evaluation in nonhuman primates (NHP). Radioligands [ carbonyl-11C]4-6 were produced and isolated in high radioactivity (>1000 MBq), radiochemical purity (>99%), and moderate molar activity (19-28 GBq/μmol at time of injection) using a palladium-mediated 11C-aminocarbonylation protocol. All three radioligands showed high brain permeability as well as a regional brain radioactivity distribution in accordance with H3R expression (striatum > cortex > cerebellum). [ Carbonyl-11C]6 displayed the most favorable in vivo kinetics and brain uptake, with an early peak in the striatal time-activity curve followed by a progressive washout from the brain. The specificity and on-target kinetics of [ carbonyl-11C]6 were next investigated in pretreatment and displacement studies. After pretreatment or displacement with 5 (0.1 mg/kg), a uniformly low distribution of radioactivity across the NHP brain was observed. Collectively, this work demonstrates that [ carbonyl-11C]6 is a promising candidate for H3R imaging in human subjects.
Collapse
Affiliation(s)
- Kenneth Dahl
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Ryuji Nakao
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Nahid Amini
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Mohammad Mahdi Moein
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Sjoerd Finnema
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Jonas Malmquist
- PET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, S-171 76 Stockholm, Sweden
| | - Katarina Varnäs
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
| | - Magnus Schou
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden
- PET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, S-171 76 Stockholm, Sweden
| |
Collapse
|
5
|
Łażewska D, Kieć-Kononowicz K. Progress in the development of histamine H 3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat 2018; 28:175-196. [PMID: 29334795 DOI: 10.1080/13543776.2018.1424135] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Since years, ligands blocking histamine H3 receptor (H3R) activity (antagonists/inverse agonists) are interesting targets in the search for new cures for CNS disorders. Intensive works done by academic and pharmaceutical company researchers have led to many potent and selective H3R antagonists/inverse agonists. Some of them have reached to clinical trials. AREAS COVERED Patent applications from January 2013 to September 2017 and the most important topics connected with H3R field are analysed. Espacenet, Patentscope, Pubmed, GoogleScholar or Cochrane Library online databases were principially used to collect all the materials. EXPERT OPINION The research interest in histamine H3R field is still high although the number of patent applications has decreased during the past 4 years (around 20 publications). Complexity of histamine H3R biology e.g. many isoforms, constitutive activity, heteromerization with other receptors (dopamine D2, D1, adenosine A2A) and pharmacology make not easy realization and evaluation of therapeutic potential of anti-H3R ligands. First results from clinical trials have verified potential utility of histamine H3R antagonist/inverse agonists in some diseases. However, more studies are necessary for better understanding of an involvement of the histaminergic system in CNS-related disorders and helping more ligands approach to clinical trials and the market. Lists of abbreviations: hAChEI - human acetylcholinesterase inhibitor; hBuChEI - human butyrylcholinesterase inhibitor; hMAO - human monoamine oxidase; MAO - monoamine oxidase.
Collapse
Affiliation(s)
- Dorota Łażewska
- a Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Kraków , Poland
| | - Katarzyna Kieć-Kononowicz
- a Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Kraków , Poland
| |
Collapse
|
6
|
Hanyu M, Kawamura K, Takei M, Furutsuka K, Shiomi S, Fujishiro T, Ogawa M, Nengaki N, Hashimoto H, Fukumura T, Zhang MR. Radiosynthesis and quality control of [ 11 C]TASP457 as a clinically useful PET ligand for imaging of histamine H 3 receptors in human brain. Nucl Med Biol 2016; 43:679-684. [DOI: 10.1016/j.nucmedbio.2016.08.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 07/12/2016] [Accepted: 08/06/2016] [Indexed: 10/21/2022]
|
7
|
Cheng G, Werner TJ, Newberg A, Alavi A. Failed PET Application Attempts in the Past, Can We Avoid Them in the Future? Mol Imaging Biol 2016; 18:797-802. [DOI: 10.1007/s11307-016-1017-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
8
|
Schou M, Varnäs K, Jureus A, Ahlgren C, Malmquist J, Häggkvist J, Tari L, Wesolowski SS, Throner SR, Brown DG, Nilsson M, Johnström P, Finnema SJ, Nakao R, Amini N, Takano A, Farde L. Discovery and Preclinical Validation of [(11)C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. ACS Chem Neurosci 2016; 7:177-84. [PMID: 26529287 DOI: 10.1021/acschemneuro.5b00268] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
UNLABELLED The histamine type 3 receptor (H3) is a G protein-coupled receptor implicated in several disorders of the central nervous system. Herein, we describe the radiolabeling and preclinical evaluation of a candidate radioligand for the H3 receptor, 4-(1S,2S)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]-N-methyl-benzamide (5), and its comparison with one of the frontrunner radioligands for H3 imaging, namely, GSK189254 (1). Compounds 1 and 5 were radiolabeled with tritium and carbon-11 for in vitro and in vivo imaging experiments. The in vitro binding of [(3)H]1 and [(3)H]5 was examined by (i) saturation binding to rat and nonhuman primate brain tissue homogenate and (ii) in vitro autoradiography on tissue sections from rat, guinea pig, and human brain. The in vivo binding of [(11)C]1 and [(11)C]5 was examined by PET imaging in mice and nonhuman primates. Bmax values obtained from Scatchard analysis of [(3)H]1 and [(3)H]5 binding were in good agreement. Autoradiography with [(3)H]5 on rat, guinea pig, and human brain slices showed specific binding in regions known to be enhanced in H3 receptors, a high degree of colocalization with [(3)H]1, and virtually negligible nonspecific binding in tissue. PET measurements in mice and nonhuman primates demonstrated that [(11)C]5 binds specifically and reversibly to H3 receptors in vivo with low nonspecific binding in brain tissue. Whereas [(11)C]1 showed similar binding characteristics in vivo, the binding kinetics appeared faster for [(11)C]5 than for [(11)C]1. CONCLUSIONS [(11)C]5 has suitable properties for quantification of H3 receptors in nonhuman primate brain and has the potential to offer improved binding kinetics in man compared to [(11)C]1.
Collapse
Affiliation(s)
- Magnus Schou
- AstraZeneca Translational
Science Centre at Karolinska Institutet, PET Centre of Excellence,
Department of Clinical Neuroscience, S-17176 Stockholm, Sweden
| | - Katarina Varnäs
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Anders Jureus
- AstraZeneca, Research & Development, Innovative Medicines, S-151 85 Södertälje, Sweden
| | - Charlotte Ahlgren
- AstraZeneca, Research & Development, Innovative Medicines, S-151 85 Södertälje, Sweden
| | - Jonas Malmquist
- AstraZeneca, Research & Development, Innovative Medicines, S-151 85 Södertälje, Sweden
| | - Jenny Häggkvist
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Lenke Tari
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Steven S. Wesolowski
- AstraZeneca, Research & Development, Innovative Medicines, Cambridge, Massachusetts 02451, United States
| | - Scott R. Throner
- AstraZeneca, Research & Development, Innovative Medicines, Waltham, Massachusetts 02139, United States
| | - Dean G. Brown
- AstraZeneca, Research & Development, Innovative Medicines, Waltham, Massachusetts 02139, United States
| | - Maria Nilsson
- AstraZeneca, Research & Development, Innovative Medicines, S-151 85 Södertälje, Sweden
| | - Peter Johnström
- AstraZeneca Translational
Science Centre at Karolinska Institutet, PET Centre of Excellence,
Department of Clinical Neuroscience, S-17176 Stockholm, Sweden
| | - Sjoerd J. Finnema
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Ryuji Nakao
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Nahid Amini
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Akihiro Takano
- Department
of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Lars Farde
- AstraZeneca Translational
Science Centre at Karolinska Institutet, PET Centre of Excellence,
Department of Clinical Neuroscience, S-17176 Stockholm, Sweden
| |
Collapse
|
9
|
Mahmood D, Pillai KK, Khanam R, Jahan K, Goswami D, Akhtar M. The Effect of Subchronic Dosing of Ciproxifan and Clobenpropit on Dopamine and Histamine Levels in Rats. J Exp Neurosci 2015; 9:73-80. [PMID: 26379444 PMCID: PMC4556212 DOI: 10.4137/jen.s27244] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 06/07/2015] [Accepted: 06/22/2015] [Indexed: 01/16/2023] Open
Abstract
The present study was designed to investigate the effect of once daily for 7-day (subchronic treatment) dosing of histamine H3 receptor antagonists, ciproxifan (CPX) (3 mg/kg, i.p.), and clobenpropit (CBP) (15 mg/kg, i.p), including clozapine (CLZ) (3.0 mg/kg, i.p.) and chlorpromazine (CPZ) (3.0 mg/kg, i.p.), the atypical and typical antipsychotic, respectively, on MK-801(0.2 mg/kg, i.p.)-induced locomotor activity, and dopamine and histamine levels in rats. Dopamine and histamine levels were measured in striatum and hypothalamus, respectively, of rat brain. Atypical and typical antipsychotics were used to serve as clinically relevant reference agents to compare the effects of the H3 receptor antagonists. MK-801-induced increase of horizontal activity was reduced with CPX and CBP. The attenuation of MK-801-induced locomotor hyperactivity produced by CPX and CBP was comparable to CLZ and CPZ. MK-801 raised dopamine levels in the striatum, which was reduced in rats pretreated with CPX and CBP. CPZ also lowered striatal dopamine levels, though the decrease was less robust compared to CLZ, CPX and CBP. MK-801 increased histamine content although to a lesser degree. Subchronic treatment with CPX and CBP exhibited further increase in histamine levels in the hypothalamus compared to the MK-801 treatment alone. Histamine H3 receptor agonist, R-α methylhistamine (10 mg/kg, i.p.) counteracted the effects of CPX and CBP. In conclusion, the subchronic dosing of CPX/CBP suggests some antipsychotic-like activities as CPX/CBP counteracts the modulatory effects of MK-801 on dopamine and histamine levels and prevents MK-801-induced hyperlocomotor behaviors.
Collapse
Affiliation(s)
- D Mahmood
- Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi, India
| | - K K Pillai
- Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi, India
| | - R Khanam
- Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi, India
| | - K Jahan
- Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi, India
| | - D Goswami
- Ranbaxy Research Laboratories Ltd., Gurgoan, Haryana, India
| | - M Akhtar
- Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi, India
| |
Collapse
|
10
|
Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study. J Mol Neurosci 2015; 56:320-8. [DOI: 10.1007/s12031-015-0536-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 02/26/2015] [Indexed: 10/23/2022]
|
11
|
Lewis DY, Champion S, Wyper D, Dewar D, Pimlott S. Assessment of [125I]WYE-230949 as a novel histamine H3 receptor radiopharmaceutical. PLoS One 2014; 9:e115876. [PMID: 25542008 PMCID: PMC4277420 DOI: 10.1371/journal.pone.0115876] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Accepted: 12/02/2014] [Indexed: 12/15/2022] Open
Abstract
Histamine H3 receptor therapeutics have been proposed for several diseases such as schizophrenia, attention deficit hyperactivity disorder, Alzheimer's disease and obesity. We set out to evaluate the novel compound, [125I]WYE-230949, as a potential radionuclide imaging agent for the histamine H3 receptor in brain. [125I]WYE-230949 had a high in vitro affinity for the rat histamine H3 receptor (Kd of 6.9 nM). The regional distribution of [125I]WYE-230949 binding sites in rat brain, demonstrated by in vitro autoradiography, was consistent with the known distribution of the histamine H3 receptor. Rat brain uptake of intravenously injected [125I]WYE-230949 was low (0.11 %ID/g) and the ratio of specific: non-specific binding was less than 1.4, as determined by ex vivo autoradiography. In plasma, metabolism of [125I]WYE-230949 into a less lipophilic species occurred, such that less than 38% of the parent compound remained 30 minutes after injection. Brain uptake and metabolism of [125I]WYE-230949 were increased and specific binding was reduced in anaesthetised compared to conscious rats. [125I]WYE230949 is not a potential radiotracer for imaging rat histamine H3 receptors in vivo due to low brain uptake, in vivo metabolism of the parent compound and low specific binding.
Collapse
Affiliation(s)
- David Y. Lewis
- Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- * E-mail:
| | - Sue Champion
- Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - David Wyper
- Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Deborah Dewar
- Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Sally Pimlott
- Department of Clinical Physics, Greater Glasgow NHS Trust and University of Glasgow, Glasgow, United Kingdom
| |
Collapse
|
12
|
Funke U, Vugts DJ, Janssen B, Spaans A, Kruijer PS, Lammertsma AA, Perk LR, Windhorst AD. 11C-labeled and18F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain. J Labelled Comp Radiopharm 2013; 56:120-9. [DOI: 10.1002/jlcr.3038] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Revised: 01/18/2013] [Accepted: 01/29/2013] [Indexed: 12/13/2022]
Affiliation(s)
| | - Danielle J. Vugts
- VU University Medical Center, Department of Radiology & Nuclear Medicine; Location Radionuclide Center; De Boelelaan 1085c; 1081; HV; Amsterdam; The Netherlands
| | - Bieneke Janssen
- VU University Medical Center, Department of Radiology & Nuclear Medicine; Location Radionuclide Center; De Boelelaan 1085c; 1081; HV; Amsterdam; The Netherlands
| | | | - Perry S. Kruijer
- BV Cyclotron VU; De Boelelaan 1081; 1081; HV; Amsterdam; The Netherlands
| | - Adriaan A. Lammertsma
- VU University Medical Center, Department of Radiology & Nuclear Medicine; Location Radionuclide Center; De Boelelaan 1085c; 1081; HV; Amsterdam; The Netherlands
| | - Lars R. Perk
- BV Cyclotron VU; De Boelelaan 1081; 1081; HV; Amsterdam; The Netherlands
| | - Albert D. Windhorst
- VU University Medical Center, Department of Radiology & Nuclear Medicine; Location Radionuclide Center; De Boelelaan 1085c; 1081; HV; Amsterdam; The Netherlands
| |
Collapse
|
13
|
Buiter HJ, Windhorst AD, Huisman MC, De Maeyer JH, Schuurkes JA, Lammertsma AA, Leysen JE. Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor. EJNMMI Res 2013; 3:24. [PMID: 23557209 PMCID: PMC3623622 DOI: 10.1186/2191-219x-3-24] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Accepted: 03/22/2013] [Indexed: 01/05/2023] Open
Abstract
Background Serotonin 5-HT4 receptor (5-HT4-R) agonists are potential therapeutic agents for enterokinetic and cognitive disorders and are marketed for treatment of constipation. The aim of this study was to develop an agonist positron emission tomography (PET) ligand in order to label the active G-protein coupled 5-HT4-R in peripheral and central tissues. For this purpose prucalopride, a high-affinity selective 5-HT4-R agonist, was selected. Methods [11C]Prucalopride was synthesized from [11C]methyl triflate and desmethyl prucalopride, and its LogDoct,pH7.4 was determined. Three distinct studies were performed with administration of IV [11C]prucalopride in male rats: (1) The biodistribution of radioactivity was measured ex vivo; (2) the kinetics of radioactivity levels in brain regions and peripheral organs was assessed in vivo under baseline conditions and following pre-treatment with tariquidar, a P-glycoprotein efflux pump inhibitor; and (3) in vivo stability of [11C]prucalopride was checked ex vivo in plasma and brain extracts using high-performance liquid chromatography. Results [11C]Prucalopride was synthesized in optimised conditions with a yield of 21% ± 4% (decay corrected) and a radiochemical purity (>99%), its LogDoct,pH7.4 was 0.87. Ex vivo biodistribution studies with [11C]prucalopride in rats showed very low levels of radioactivity in brain (maximal 0.13% ID·g−1) and ten times higher levels in certain peripheral tissues. The PET studies confirmed very low brain levels of radioactivity under baseline conditions; however, it was increased three times after pre-treatment with tariquidar. [11C]Prucalopride was found to be very rapidly metabolised in rats, with no parent compound detectable in plasma and brain extracts at 5 and 30 min following IV administration. Analysis of levels of radioactivity in peripheral tissues revealed a distinct PET signal in the caecum, which was reduced following tariquidar pre-treatment. The latter is in line with the role of the P-glycoprotein pump in the gut. Conclusion [11C]Prucalopride demonstrated low radioactivity levels in rat brain; a combination of reasons may include rapid metabolism in the rat in particular, low passive diffusion and potential P-glycoprotein substrate. In humans, further investigation of [11C]prucalopride for imaging the active state of 5-HT4-R is worthwhile, in view of the therapeutic applications of 5-HT4 agonists for treatment of gastrointestinal motility disorders.
Collapse
Affiliation(s)
- Hans Jc Buiter
- Department of Radiology and Nuclear Medicine, VU University Medical Center, PO Box 7057, Amsterdam, MB, 1007, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
14
|
A new facile synthetic route to [11C]GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor. Bioorg Med Chem Lett 2012; 22:4713-8. [DOI: 10.1016/j.bmcl.2012.05.076] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2012] [Revised: 05/16/2012] [Accepted: 05/18/2012] [Indexed: 11/17/2022]
|
15
|
Buiter HJ, Leysen JE, Schuit RC, Fisher A, Lammertsma AA, Windhorst AD. Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [11C]AF150(S). J Labelled Comp Radiopharm 2012. [DOI: 10.1002/jlcr.2932] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Hans J.C. Buiter
- Department of Nuclear Medicine & PET Research; VU University Medical Center; PO Box 7057; 1007 MB; Amsterdam; The Netherlands
| | - Josée E. Leysen
- Department of Nuclear Medicine & PET Research; VU University Medical Center; PO Box 7057; 1007 MB; Amsterdam; The Netherlands
| | - Robert C. Schuit
- Department of Nuclear Medicine & PET Research; VU University Medical Center; PO Box 7057; 1007 MB; Amsterdam; The Netherlands
| | - Abraham Fisher
- Israel Institute for Biological Research; Ness-Ziona; Israel
| | - Adriaan A. Lammertsma
- Department of Nuclear Medicine & PET Research; VU University Medical Center; PO Box 7057; 1007 MB; Amsterdam; The Netherlands
| | - Albert D. Windhorst
- Department of Nuclear Medicine & PET Research; VU University Medical Center; PO Box 7057; 1007 MB; Amsterdam; The Netherlands
| |
Collapse
|
16
|
Selivanova SV, Honer M, Combe F, Isensee K, Stark H, Krämer SD, Schubiger PA, Ametamey SM. Radiofluorinated histamine H3 receptor antagonist as a potential probe for in vivo PET imaging: Radiosynthesis and pharmacological evaluation. Bioorg Med Chem 2012; 20:2889-96. [DOI: 10.1016/j.bmc.2012.03.024] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2011] [Revised: 03/05/2012] [Accepted: 03/09/2012] [Indexed: 01/16/2023]
|
17
|
Bao X, Lu S, Liow JS, Zoghbi SS, Jenko KJ, Clark DT, Gladding RL, Innis RB, Pike VW. Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype. J Med Chem 2012; 55:2406-15. [PMID: 22313227 PMCID: PMC3303611 DOI: 10.1021/jm201690h] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A known chemotype of H(3) receptor ligand was explored for development of a radioligand for imaging brain histamine subtype 3 (H(3)) receptors in vivo with positron emission tomography (PET), namely nonimidazole 2-aminoethylbenzofurans, represented by the compound (R)-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)benzofuran-5-yl)(4-fluorophenyl)methanone (9). Compound 9 was labeled with fluorine-18 (t(1/2) = 109.7 min) in high specific activity by treating the prepared nitro analogue (12) with cyclotron-produced [(18)F]fluoride ion. [(18)F]9 was studied with PET in mouse and in monkey after intravenous injection. [(18)F]9 showed favorable properties as a candidate PET radioligand, including moderately high brain uptake with a high proportion of H(3) receptor-specific signal in the absence of radiodefluorination. The nitro compound 12 was found to have even higher H(3) receptor affinity, indicating the potential of this chemotype for the development of further promising PET radioligands.
Collapse
Affiliation(s)
- Xiaofeng Bao
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Shuiyu Lu
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Jeih-San Liow
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Sami S. Zoghbi
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Kimberly J. Jenko
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - David T. Clark
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Robert L. Gladding
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Robert B. Innis
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| | - Victor W. Pike
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, Maryland, 20892, United States
| |
Collapse
|
18
|
Flik G, Dremencov E, Cremers TIHF, Folgering JHA, Westerink BHC. The role of cortical and hypothalamic histamine-3 receptors in the modulation of central histamine neurotransmission: an in vivo electrophysiology and microdialysis study. Eur J Neurosci 2011; 34:1747-55. [DOI: 10.1111/j.1460-9568.2011.07893.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Hamill TG, Sato N, Jitsuoka M, Tokita S, Sanabria S, Eng W, Ryan C, Krause S, Takenaga N, Patel S, Zeng Z, Williams D, Sur C, Hargreaves R, Burns HD. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse 2009; 63:1122-32. [DOI: 10.1002/syn.20689] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
20
|
Plisson C, Gunn RN, Cunningham VJ, Bender D, Salinas CA, Medhurst AD, Roberts JC, Laruelle M, Gee AD. 11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET. J Nucl Med 2009; 50:2064-72. [PMID: 19910432 DOI: 10.2967/jnumed.109.062919] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED The histamine H(3) receptor is a G-protein-coupled presynaptic auto- and heteroreceptor whose activation leads to a decrease in the release of several neurotransmitters including histamine, acetycholine, noradrenaline, and dopamine. H(3) receptor antagonists such as 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) can increase the release of these neurotransmitters and thus may offer potential therapeutic benefits in diseases characterized by disturbances of neurotransmission. The aim of this study was to synthesize and evaluate (11)C-labeled GSK189254 ((11)C-GSK189254) for imaging the histamine H(3) receptor in vivo by PET. METHODS GSK189254 exhibits high affinity (0.26 nM) and selectivity for the human histamine H(3) receptor. Autoradiography experiments were performed using (3)H-GSK189254 to evaluate its in vitro binding in porcine brain tissues. GSK189254 was labeled by N-alkylation using (11)C-methyl iodide in good yields, radiochemical purity, and specific activity. A series of PET experiments was conducted to investigate (11)C-GSK189254 binding in the porcine brain. RESULTS In vitro autoradiography demonstrated specific (3)H-GSK189254 binding in the porcine brain; therefore, (11)C-GSK189254 was evaluated in vivo in pigs and showed good brain penetration and high uptake in regions such as the striatum and cortices, known to contain high densities of the histamine H(3) receptors. The radioligand kinetics were reversible, and quantitative analysis was achieved with a 2-tissue-compartmental model yielding the distribution volume as the outcome measure of interest. The distribution volume was reduced to a homogeneous level in all regions after blocking by the coadministration of either unlabeled GSK189254 or ciproxifan, a structurally distinct histamine H(3) antagonist. Further coadministration studies allowed for the estimation of the radioligand affinity (0.1 nM) and the density of histamine H(3) receptor sites in the cerebellum (0.74 nM), cortex (2.05 nM), and striatum (2.65 nM). CONCLUSION These findings suggest that (11)C-GSK189254 possesses appropriate characteristics for the in vivo imaging of the histamine H(3) receptor by PET.
Collapse
Affiliation(s)
- Christophe Plisson
- GlaxoSmithKline, Clinical Imaging Centre, Hammersmith Hospital, London, United Kingdom.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Development of a selective and potent radioactive ligand for histamine H3 receptors: A compound potentially useful for receptor occupancy studies. Bioorg Med Chem Lett 2009; 19:4075-8. [DOI: 10.1016/j.bmcl.2009.06.025] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2009] [Revised: 06/02/2009] [Accepted: 06/03/2009] [Indexed: 11/19/2022]
|
22
|
Miller TR, Milicic I, Bauch J, Du J, Surber B, Browman KE, Marsh K, Cowart M, Brioni JD, Esbenshade TA. Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol 2009; 157:139-49. [PMID: 19413577 DOI: 10.1111/j.1476-5381.2009.00239.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE The histamine H3 receptor antagonist radioligand [3H]-A-349821 was characterized as a radiotracer for assessing in vivo receptor occupancy by H3 receptor antagonists that affect behaviour. This model was established as an alternative to ex vivo binding methods, for relating antagonist H3 receptor occupancy to blood levels and efficacy in preclinical models. EXPERIMENTAL APPROACH In vivo cerebral cortical H3 receptor occupancy by [3H]-A-349821 was determined in rats from differences in [3H]-A-349821 levels in the isolated cortex and cerebellum, a brain region with low levels of H3 receptors. Comparisons were made to relate antagonist H3 receptor occupancy to blood levels and efficacy in a preclinical model of cognition, the five-trial inhibitory avoidance response in rat pups. KEY RESULTS In adult rats, [3H]-A-349821, 1.5 microg x kg(-1), penetrated into the brain and cleared more rapidly from cerebellum than cortex; optimally, [3H]-A-349821 levels were twofold higher in the latter. With increasing [3H]-A-349821 doses, cortical H3 receptor occupancy was saturable with a binding capacity consistent with in vitro binding in cortex membranes. In studies using tracer [3H]-A-349821 doses, ABT-239 and other H3 receptor antagonists inhibited H3 receptor occupancy by [3H]-A-349821 in a dose-dependent manner. Blood levels of the antagonists corresponding to H3 receptor occupancy were consistent with blood levels associated with efficacy in the five-trial inhibitory avoidance response. CONCLUSIONS AND IMPLICATIONS When employed as an occupancy radiotracer, [3H]-A-349821 provided valid measurements of in vivo H3 receptor occupancy, which may be helpful in guiding and interpreting clinical studies of H3 receptor antagonists.
Collapse
Affiliation(s)
- T R Miller
- Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Sander K, Kottke T, Stark H. Histamine H3 Receptor Antagonists Go to Clinics. Biol Pharm Bull 2008; 31:2163-81. [DOI: 10.1248/bpb.31.2163] [Citation(s) in RCA: 162] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Kerstin Sander
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| | - Tim Kottke
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| | - Holger Stark
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| |
Collapse
|
24
|
Funaki Y, Sato K, Kato M, Ishikawa Y, Iwata R, Yanai K. Evaluation of the binding characteristics of [18F]fluoroproxyfan in the rat brain for in vivo visualization of histamine H3 receptor. Nucl Med Biol 2007; 34:981-7. [DOI: 10.1016/j.nucmedbio.2007.07.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2007] [Revised: 07/10/2007] [Accepted: 07/18/2007] [Indexed: 10/22/2022]
|
25
|
Chapter 4 Recent Advances in Drug Discovery of Histamine H3 Antagonists. ANNUAL REPORTS IN MEDICINAL CHEMISTRY VOLUME 42 2007. [DOI: 10.1016/s0065-7743(07)42004-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|